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Glaucoma is defined as an optic neuropathy, characterized for loss of visual field and injury of the optic 
nerve, being considered as the second cause of blindness in the world, which could be prevented by the use 
of antiglaucoma eyedrops. The lack of adhesion of the patient to the drug treatment can culminate with loss of 
the vision. The objective was to revise possible literature data regarding intervening factors for noncompliance 
and explain estimated rates of noncompliance. A systematic review about the subject was carried out in the 
period of January to June of 2006. Articles had been searched in two data bases, in the National Library of 
Medicine (PUBMED) and in the Literature Latin American and Caribbean Health Sciences (LILACS) using 
the following keywords: glaucoma, compliance of the patient, noncompliance of the patient, treatment and 
eyedrops. In PUBMED, 199 articles were collected, written in English and French languages. No article was 
found in LILACS. Considering the inclusion and exclusion criteria, 27 articles were selected, with 25 originals 
and two reviews. Twelve possible intervening factors for noncompliance were raised, as well as estimates for 
rates of noncompliance. The noncompliance rates varied from 4.6% up to 59%. Two factors, forgetfulness and 
inadequate between-doses interval, had been associated to noncompliance of the drug therapy. The factors race, 
adverse effects, treatment cost, number of instilled doses, coexisting illnesses and number of eyedrops used, 
had resulted contradictory, being impossible to affirm that they have contributed for noncompliance. Age, sex, 
educational level and loss of visual field, had not been associated with noncompliance. The glaucoma patients 
tended to disregard the drug treatment. The wide variation in noncompliance rates could be an influence from 
the authors’ difficulty to define the noncompliance and the variety of methodologies used to estimate it. More 
studies are necessary for a better evaluation of these 12 raised factors.
Uniterms: Glaucoma/drug treatment. Drug treatment/adhesion. Eyedrops/use/evaluation.
O glaucoma é definido como uma neuropatia óptica, caracterizada por perda de campo visual e lesão do nervo 
óptico, sendo considerado como a segunda causa de cegueira no mundo, podendo ser evitada pelo uso de colírios 
antiglaucomatosos. A falta de adesão ao tratamento medicamentoso pode culminar com perda da visão. O 
objetivo do trabalho foi revisar dados da literatura a respeito de possíveis fatores intervenientes para a não adesão 
à terapêutica medicamentosa e relatar taxas de não adesão estimadas. Foi realizada uma revisão sistematizada 
sobre o assunto, abrangendo o período de janeiro a junho de 2006. Foram pesquisados artigos em dois bancos de 
dados, o da National Library of Medicine (PUBMED) e o de Literatura Latino Americana e do Caribe em Ciências 
da Saúde (LILACS), utilizando-se as seguintes palavras-chave: glaucoma, adesão do paciente, não adesão do 
paciente, tratamento e colírios. Foram levantados 199 artigos no PUBMED, nas línguas inglesa e francesa. Não 
foram encontrados artigos no LILACS. A partir dos critérios de inclusão e exclusão, foram selecionados 27 artigos, 
sendo 25 originais e duas revisões. Foram averiguados 12 possíveis fatores intervenientes para não adesão, bem 
como estimativas de taxas de não cooperação ao tratamento. As taxas de não adesão variaram de 4,6% a 59%. 
Dois fatores, ‘esquecimento’ e ‘intervalo inadequado entre as doses’, foram associados ao não-cumprimento da 
terapêutica medicamentosa. Raça, custo do tratamento, efeitos adversos, número de doses instiladas, doenças 
coexistentes e número de colírios utilizados tiveram resultados contraditórios, não podendo afirmar-se que os 
mesmos contribuíram para a não adesão. Idade, sexo, nível de escolaridade e perda de campo visual não foram 
associados à não adesão. Os pacientes glaucomatosos tenderam a descumprir o tratamento medicamentoso. A 
ampla variação nas taxas de não adesão pode ter sido influenciada pela dificuldade dos autores em definir a não 
adesão e pela variância de metodologias aplicadas para estimar a mesma. Mais estudos são necessários para 
uma melhor avaliação destes 12 possíveis fatores levantados.
Unitermos: Glaucoma/terapêutica medicamentosa. Tratamento medicamentoso/adesão. Colírios/uso/
avaliação.
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INTRODUCTION
The glaucoma is defined, currently, as an optic neuro-
pathy, characterized for loss of visual field and injury of the 
optic nerve (Rait, 2000), being the increase of the intra-ocular 
pressure (IOP) considered as a risk factor (Quigley, 1996). 
According to World Health Organization (WHO), glaucoma 
is the second worldwide cause of blindness (Kingman, 2004), 
with about 5.2 million blind people (Wilensky, 1996).
The blindness caused for this disease is irreversible 
(Coleman, 1999), being possible to prevent it through drug 
treatment with the use of eyedrops or surgical intervention. 
Normally, the first line of treatment is the drug therapy (Tsai 
et al., 2003). 
The success of the therapeutic drug depends strictly 
on the patient’s compliance, that is, on the correspondence 
of patient’s behavior when using the medicines, with the 
medical recommendations (Schwartz, 2005). The lack of 
fulfillment to the drug treatment can culminate with the 
patient’s vision loss (Stewart, Konstas, Pfeiffer, 2004). This 
is a worrying fact, as Patel & Spaeth (1995) had found 59% 
of noncompliant patients. Some authors (Bloch et al., 1977; 
Kass et al., 1987; Patel, Spaeth, 1995; Nordström et al., 2005) 
have found possible intervening factors for noncompliance 
to antiglaucoma therapy, with quite changeable results. In 
such a way, the proposal of this article is to make a review 
of literature data regarding the possible intervening factors 
for noncompliance to therapeutic regime, as well as, to find 
estimated rates for noncompliance. 
MATERIAL AND METHODS 
A systematic review about the subject was carried out 
in the period of January to June of 2006. Articles have been 
searched in two data bases, in the National Library of Medi-
cine (PUBMED) and in the Literature Latin American and 
Caribbean Health Sciences (LILACS). The key words used in 
the research was: glaucoma, compliance of the patient, non-
compliance of the patient, treatment and eyedrops. The search 
has included articles written in the English, French, Spanish 
and Portuguese languages, obeying the following priority 
order: glaucoma and compliance of the patient; glaucoma 
and noncompliance of the patient; glaucoma, compliance of 
the patient and eyedrops; glaucoma, noncompliance of the 
patient and eyedrops; glaucoma, compliance of the patient 
and treatment; glaucoma, noncompliance of the patient and 
treatment; compliance of the patient, eyedrops and treatment, 
and noncompliance of the patient, eyedrops and treatment. 
Articles published in the last 30 years were raised; between 
June, 1976 and June, 2006. 
This review has included articles dealing with causes 
or intervening factors in the compliance to glaucoma drug 
treatment and estimated rates of compliance and/or non-
compliance to glaucoma drug treatment; these articles were 
indexed to the used data base and had their available sum-
maries over there. Those using invasive methods (methods 
using needles and/or catheters for blood collection with 
purpose of drugs dosage) for evaluation of the compliance; 
analyzing compared antiglaucomatous effect; approaching 
exclusively the persistence to glaucoma drug treatment of; 
focusing the improvement or increase of compliance to 
glaucoma drug treatment ; and having no known author-
ship were excluded. The interest data were collected and 
presented as text and tables. 
Initially, 199 articles in the PUBMED, in English and 
French languages were raised. Articles in the LILACS were 
not found. Based on the inclusion and exclusion criteria, 27 
articles were selected, being 25 originals and two reviews 
(Table I.)
The noncompliance rates found in this review varied 
from 4.6% to 59%, as demonstrated in Table II.
Twelve possible intervening factors had been found for 
noncompliance of glaucoma therapy: sex, age, race, adverse 
effect, number of instilled doses, number of used eyedrops, 
treatment cost, educational level, inadequate between doses 
interval, coexisting illnesses, forgetfulness and loss of visual 
field. The factors - forgetfulness and inadequate between 
doses interval- apparently contributed positively for noncom-
pliance to glaucoma therapy. 
Possible intervening factors
Sex
Bloch et al. (1977) had shown in their 40 patients study, 
that men adhere little to the antiglaucomatous treatment than 
women (χ2 = 3.79, p < 0.1). Patel & Spaeth (1995) suggested 
that men have higher trend to leave to use their eyedrops as 
compared to women, however, the cumulative data weren`t 
statistically significant (χ2 = 1,35, p < 0,24). Seven works 
pointed the inexistence of significant association of sex with 
noncompliance to treatment (Bour, Blanchard, Segal, 1993; 
Gurwitz et al., 1993; Rotchford, Murphy, 1998; Gurwitz et 
al., 1998; Kosoko et al., 1998; Wane et al., 2003; Khandekar, 
Shama, Mohammed, 2005). 
Age
A study developed for Rocheblave (1983) in a French 
agricultural area, showed that patients aged more than 65 ye-
ars cooperate better for the treatment, although the quantified 
data (in percentage) do not indicate this trend with precision. 
In another French work described for Bour; Blanchard and 
Segal (1993), the factor age does not significantly intervene 
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with patient’s noncompliance (p = 0.42). Gurwitz et al. (1993) 
didn´t find significant difference in noncompliance between 
patients of different age strata: 65-74 years, 75-84 years and 
85 years or more. Rotchford and Murphy (1998), Kosoko et 
al. (1998), Gurwitz et al. (1998), Wane et al. (2003), Khan-
dekar, Shama & Mohammed (2005) and Sleath et al. (2006), 
have also concluded that age is not significantly associated 
with noncompliance.
Race
Gurwitz et al. (1993) divided the study participants in 
three racial groups: ‘Caucasian’, ‘Afro-American’ and ‘oth-
ers’. There was no difference in the compared noncompliance 
rates between the Caucasian and Afro-American groups. 
On the other hand, when these two groups were compared 
with the ‘others’ group, a longer and significant period of 
days without treatment was noticed in this last racial group. 
Patel & Spaeth (1995) compared the non-adhesion indexes 
between Caucasian and Afro-American, arriving at the 
conclusion that, statistically, the race would be a delinquent 
factor (limit) between compliance and noncompliance (χ2 = 
1.22, p = 0.27). In another research of Kosoko et al. (1998), 
the races were compared in only two groups, black and non-
black people. Cumulative results were analyzed by means of 
multiple logistic regression. This work concluded that race 
wasn´t a factor for noncompliance risk . 
Adverse effect
Bloch et al. (1977) found that 7 (64%) not adherent 
and 9 (31%) adherent patients interrupted their treatment 
because of the adverse effect (χ2 = 3.53, p < 0.1). Granströn 
& Norell (1983) noticed the occurrence of adverse effect in 
54 of 78 patients using pilocarpine, but the non-adhesion 
rate wasn’t significantly higher between patients exhibiting 
adverse effect (p > 0.20). Another study developed for Kass 
et al. (1987) pointed a higher adhesion on the part of patients 
using timolol maleate, when compared with those making 
use of pilocarpine, a fact related to the lower incidence of 
adverse effects of timolol maleate. Similarly to Bloch et al. 
(1977) study, Patel & Spaeth (1995) compared the presence 
of adverse effects in compliant and noncompliant patients, 
but, no significant influence for noncompliance was noticed 
(χ2 = 1.42, p = 0.23). Gurwitz et al. (1998), Rotchford & 
Murphy (1998) and Taylor, Galbraith and Mills (2002) have 
not correlated the presence of adverse effects with adhesion 
problems. Taylor, Galbraith and Mills (2002) verified that 
almost 10% of patients (2 in 21) left to use the eyedrops due 
to adverse effects. In a study on the classification of barriers 
for adhesion to glaucoma treatment, 27% of patients told 
that adverse effects confused or became difficult the use of 
eyedrops (Tsai et al., 2003). Deokule, Sadiq and Shah (2004) 
noticed a prevalence of about 30% of adverse effects in the 
systemic level. Respiratory difficulty (14%), nocturnal dys-
pnea (7.6%), ankle edema (4%), and migraines (3.4%) were 
the most frequent events, suggesting that these effects could 
also have some contribution for noncompliance to the treat-
ment. Sleath et al. (2006)pointed adverse effects as one of 
the main factors with respect to non-adhesion, being pointed 
by 16% of the patients.
Number of Instilled Doses
In a study of Norell (1981) where the patients used 
three times a day pilocarpine, it was noticed that evening 
doses were lost more frequently than morning (χ2 = 115.35, 
p ~ 0) and night doses (χ2 = 61.82, p ~ 0), indicating an adhe-
sion improvement in drug regimens containing as a maximum 
TABLE I - Selected articles for review study
 
Authors Publication year
Bloch et al. 1977
Norell 1981
Granström 1982
Kass et al. 1982
Granström and Norell 1983
Rocheblave 1983
Granström 1985
Kass et al. 1986
Kass et al. 1987
Winfield et al. 1990
Bour et al. 1993
Gurwitz et al. 1993
Patel and Spaeth 1995
Gurwitz et al. 1998
Kosoko et al. 1998
Rotchford and Murphy 1998
Taylor et al. 2002
Tsai et al. 2003
Wane et al. 2003
Deokule et al. 2004
Stewart et al. 2004
Nordström et al.  2005
Khandekar et al. 2005
Olthoff et al.* 2005
Robin and Covert 2005
Schwartz* 2005
Sleath et al. 2006
*Review articles
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two daily applications. Granström & Norell (1983) have 
found good treatment adhesion independently of the number 
of daily applications. A comparison of two works, Kass et al. 
(1986) and Kass et al. (1987), disclosed that patients using 
pilocarpine four times a day had a lower adhesion rate than 
patients instilling maleate of timolol two times a day, 76% 
vs. 82.7%, respectively. Patients using the eyedrops more 
times a day, had a higher trend to disregard the treatment, as 
proven for Gurwitz et al. (1993). In this study, the patients 
who instilled eyedrops three or more times a day, exhibited a 
significantly higher rate of non-adhesion, as compared with 
those dripping eyedrops one or two times a day. Gurwitz et 
al. (1998) haven`t proved a significant association between 
the administration protocols and noncompliance.
Number of eyedrops
Granström & Norell (1983) have shown that the 
number of used eyedrops didn´t intervene on treatment non-
compliance (r = -0.04). Kass et al. (1987) verified a higher 
adhesion rate to treatment with timolol maleate associated 
with other antiglaucomatous medicines, than when used 
separately, 86.1% vs. 78.6%, respectively. Patients dealing 
with a single medication are significantly more inclined to 
be non-adherent (Gurwitz et al., 1993). In the Tsai et al. 
(2003) study, a half of patients stated that the application of 
a single eyedrops medication every day, does not facilitate 
the adhesion to therapeutic regimen. Amongst patients parti-
cipating in this study, 86% had used more than one eyedrops 
medication every day. A study described by Robin & Covert 
(2005) concluded that the addition of a second medicine 
to therapeutics increased significantly the interval for 
the medicine dispensing, having a consequent decrease in 
adhesion (p < 0,0001). In a recent work, Sleath et al. (2006) 
got similar results as Granström and Norell (1983).
Treatment Cost
Kosoko et al. (1998), in a case-control study, have 
found four patients pointing the cost as intervening factor 
for non-adhesion. Amongst these patients, three were non-
adherent. The statistical comparison of data wasn’t possible 
TABLE II - Rates of noncompliance to the drug treatment
Authors Noncompliance rates Methodologies Definitions for noncompliance
Bloch et al., 1977 27.5% Interview Loss of more than 1 dose per week
Kass et al., 1982 41.8%
12.8%
Interview Loss of more than 1 dose per month
Loss of more than 1 dose per week
Kass et al., 1986 24.5% Monitor* Loss of doses for one day in the month
Kass et al., 1987 47.3% Monitor* Loss of doses for one day in the month
Winfield et al., 1990 16% Interview Loss of 2 or more doses per week
Bour et al., 1993 32% Interview Not defined
Gurwitz et al., 1993 23.3% Prescription dispensing To leave to get a new prescription during the 
following 12 months after first lapse
Patel & Spaeth, 1995 59% Interview Not defined
Rotchford and Murphy, 1998 24% Interview Not defined
Gurwitz et al., 1998 24.7% Prescription dispensing To leave to get medicines for at least 80% of the 
study days 
Tsai et al., 2003 8%
15%
Interview Loss of 1 dose in 14 days
Loss of 1 dose per week
Stewart et al., 2004 34% Interview Not defined
Deokule et al., 2004
Nordström et al., 2005
13.8%
4.6%
4.6%
50%
Interview
Prescription dispensing
Loss of 1 dose in 14 days
Loss of 2 doses in 14 days
Loss of more than 2 doses in 14 days
To leave to get medicines for periods longer than 
60 or 120 days (depending on the bottle size), in 
a period of 3 years.
* Device connected to eyedrops bottles, which memorizes (electronically) the number of drops and times that the eyedrops were 
instilled by the patient, storing the instillation schedules as well. 
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due to small number of involved patients. Patients thought the 
cost for acquisition of antiglaucomatous eyedrops medica-
tion was high, but they didn`t leave to use it due to this factor 
(Granström, Norell, 1983). On the other hand, patients told 
to leave the use the eyedrops medication, if their health plans 
left to pay for it (Tsai et al., 2003). Khandekar, Shama and 
Mohammed (2005) verified that the treatment cost wasn`t 
a significant factor for noncompliance [RR =1.29; (95% IC 
0.5-3.34)]. Nordström et al. (2005) concluded that, despite the 
higher cost of the prostaglandin-analog eyedrops, the patients 
using these medicines exhibited better adhesion as compared 
to those using β-blocker, α-agonist, miotic and carbonic 
anhydrase inhibitor eyedrops. Sleath et al. (2006) shown 
that 41% of patients had difficulty to pay for their eyedrops, 
pointing the treatment cost as one of the main factors related 
to noncompliance to treatment. 
Educational Level
Five studies have shown that educational level did not 
contribute for noncompliance to drug treatment (Patel, Spae-
th, 1995; Kosoko et al., 1998; Wane et al., 2003; Khandekar, 
Shama, Mohammed, 2005; Sleath et al., 2006), in Wane et 
al. (2003) and Khandekar, Shama and Mohammed (2005) 
studies, it was noticed a considerable ratio of illiterates in the 
study samples, of 38.7% and 67.6%, respectively. 
Inadequate between doses interval 
Kass et al. (1982, 1986, 1987) and Granström (1982) 
have shown a trend of patients to instill eyedrops rejecting the 
schedules prescribed by doctors, with increase in the number 
instilled doses during the morning and evening periods. The 
inadequate interval between doses of antiglaucomatous eye-
drops is a contributing factor for noncompliance, as disclosed 
for some studies (Patel, Spaeth, 1995; Kosoko et al., 1998; 
Wane et al., 2003; Khandekar, Shama, Mohammed, 2005). 
Coexisting illnesses 
Bloch et al. (1977) have significantly associated the 
presence of chronic illnesses, such as diabetes, hypertension, 
arthritis and atherosclerosis, with noncompliance to therapeu-
tic drug (χ2 = 4.36, p < 0.05). Contrarily, Bour, Blanchard 
and Segal (1993) and Gurwitz et al. (1998) have not found 
significant differences correlating the presence of coexisting 
illnesses with noncompliance. 
Forgetfulness
Bour, Blanchard and Segal (1993) have shown that 
52.9% of the patients did not follow the treatment because 
they forgot to drip the eyedrops. Patel & Spaeth (1995) have 
statistically compared the forgetfulness with adhesion, and 
haven`t found a positive association for noncompliance to 
therapeutic drug (p < 0.05). The work of Taylor, Galbraith 
and Mills (2002) pointed out forgetfulness as the main reason 
for noncompliance to pharmacological treatment, being also 
this factor considered as a barrier with respect to adhesion, 
for Tsai et al. (2003). Sleath et al. (2006) have also associated 
forgetfulness with treatment noncompliance. 
Loss of Visual field 
Granström (1985) hasn`t verified significant statistical 
difference between the progression of visual field loss and 
noncompliance to drug treatment (p = 0,54). Similar result 
was obtained by Gurwitz et al. (1998).
DISCUSSION
The cumulative rates of noncompliance exhibited va-
lues between 4.6% and 59%. This ample variation could be, 
in part, due to different concepts and methodologies applied 
for noncompliance evaluation, showing also a patients trend 
to disrespect the treatment with antiglaucomatous eyedrops. 
In accordance with data raised from literature, eight of 12 
possible intervening factors exhibited at least a story in lite-
rature trending to drug noncompliance. The factors ‘forget-
fulness’ and ‘inadequate between doses interval’ seemed to 
positively contribute for noncompliance to therapeutic drug 
for glaucoma. Age, sex, educational level and loss of visual 
field were not significantly associated with noncompliance 
to drug treatment. Olthoff et al. (2005), in a review article, 
have found similar results about these factors. 
Other possible intervening factors - race, adverse 
effects, treatment cost , number of instilled doses, number of 
used eyedrops, coexisting illnesses - resulted contradictory, 
being impossible to determine their actual intervenience 
for noncompliance to treatment. Amongst these factors, the 
‘number of used eyedrops’ was the more conflicting one. In 
two works, Sleath et al. (2006) and Taylor, Galbraith and 
Mills (2002), the number of instilled eyedrops did not interve-
ne for noncompliance. In other three works, Tsai et al. (2003), 
Kass et al. (1987) and Bour, Blanchard and Segal (1993), 
better adhesion was associated to the use of more than one 
eyedrops. Contrarily, Robin and Covert (2005) have shown 
that the addition of one medicine to therapeutics decreased 
the compliance. Some considerations could still be made 
respecting the factors ‘adverse effects’ and ‘cost of the treat-
ment’. The factor ‘adverse effects’, although not statistically 
associated to noncompliance, was described in some works 
(Taylor, Galbraith, Mills, 2002; Tsai et al., 2003; Deokule, 
Sadiq, Shah, 2004; Sleath et al., 2006) as one of the main 
barriers for the eyedrops instillation. Respecting to ‘treatment 
cost’ , this factor does not statistically intervene significantly 
for noncompliance, as demonstrated by Khandekar, Shama, 
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Mohammed (2005); however, as the supply of eyedrops 
medication was free of charge for individuals participating 
in this study, such situation could have influenced the statis-
tical analysis of data. In the study developed for Sleath et al. 
(2006), where free of charge medicine supply didn’t occur, 
41% of the patients had difficulties to pay for their eyedrops.
CONCLUSIONS
The daily instillation of eyedrops is the main form of 
treatment of glaucoma, hindering the illness advance and 
preventing, consequently, the loss of vision in glaucomatous. 
Our literary review showed that glaucomatous patients have 
tended to do not fulfill adequately the drug treatment, as 
demonstrated by the found rates of noncompliance, which 
varied from 4.6% to 59%. This ample variation could be 
influenced by the difficulty, on the part of the authors, in 
defining noncompliance, and, even, by the variance of me-
thodologies used for the determination of the noncompliance 
rates. Amongst the 12 possible factors raised as intervening 
for noncompliance, only two - ‘forgetfulness’ and ‘inadequate 
between doses interval’ - seemed to significantly contribute 
for noncompliance. The factors - ‘treatment cost’ and ‘adverse 
effect’ - although having not significantly been associated 
with noncompliance, have been pointed out as possible bar-
riers the drug adhesion. It has been noticed that men tended 
to adhere little to treatment than women. More studies are 
necessary for a better evaluation of these possible intervening 
factors for noncompliance to glaucoma drug treatment. 
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